Novel blood lipid lowering composition

Abstract

The invention discloses a novel blood lipid lowering composition, which is a medicinal composition comprising aliskiren and a medicinal salt thereof, a hydrate and 1-2 of statin, fibrate and nicotinic acid lipid lowering medicaments, serving as active ingredients. The composition can be prepared into oral tablets or capsules for treating hyperlipidemia; and the curative effect of the composition is superior to that of the conventional common lipid lowering medicament.

Description

technical field [0001] The invention relates to a novel blood fat-lowering composition, which belongs to the technical field of medicine. Background technique [0002] Hyperlipidemia refers to high cholesterol (TC) and / or triglyceride (TG) or low high-density lipoprotein cholesterol (HDL-C) in the blood. The damage to the body of the disease is hidden, gradual, progressive and systemic. sexual. Its direct damage is to accelerate systemic atherosclerosis, because vital organs of the whole body rely on arterial blood supply and oxygen supply. Once the arteries are blocked by atherosclerotic plaques, serious consequences will result. Renal failure caused by arteriosclerosis is closely related to hyperlipidemia. A large number of research data show that hyperlipidemia is an independent and important risk factor for stroke, coronary heart disease, myocardial infarction, and sudden cardiac death. In recent years, a variety of blood lipid-lowering drugs have been launched one af...

AI Technical Summary

Problems solved by technology

In recent years, a variety of blood lipid-lowering drugs have been launched one after another, which has increased the safety of patients with hyperlipidemia, but the therapeutic effect is still not ideal, so seeking a good and stable blood lipid-lowering drug is still the direction of new drug development in the future

Images